The delays are making a lot of people nervous. I definitely think further testing will be needed. Not bad news, but the market has priced-in the approval. So a re-rating of this stock subject to the cost of further trials, and dilution due to partnering will be on the cards.
The 300 million market cap couldn't last forever, and I look on this as a "healthy" correction.
